Standout Papers

Improved survival in multiple myeloma and the impact of novel therapies 2007 2026 2013 2019 1.6k
  1. Improved survival in multiple myeloma and the impact of novel therapies (2007)
    Shaji Kumar, S. Vincent Rajkumar et al. Blood
  2. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (2013)
    Shaji Kumar, Angela Dispenzieri et al. Leukemia
  3. Multiple myeloma (2017)
    Shaji Kumar, S. Vincent Rajkumar et al. Nature Reviews Disease Primers
  4. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study (2009)
    Ola Landgren, Robert A. Kyle et al. Blood
  5. Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements (2012)
    Shaji Kumar, Angela Dispenzieri et al. Journal of Clinical Oncology
  6. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurement and Cardiac Biomarkers: Impact on Survival Outcomes (2012)
    Giovanni Palladini, Angela Dispenzieri et al. Journal of Clinical Oncology
  7. Clonal competition with alternating dominance in multiple myeloma (2012)
    Jonathan J. Keats, Marta Chesi et al. Blood
  8. Multiple Myeloma: Diagnosis and Treatment (2016)
    S. Vincent Rajkumar, Shaji Kumar Mayo Clinic Proceedings
  9. Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance (2018)
    Robert A. Kyle, Dirk R. Larson et al. New England Journal of Medicine
  10. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial (2020)
    Shaji Kumar, Simon J. Harrison et al. The Lancet Oncology
  11. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (2023)
    Sham Mailankody, Jeffrey Matous et al. Nature Medicine

Immediate Impact

3 by Nobel laureates 5 from Science/Nature 80 standout
Sub-graph 1 of 18

Citing Papers

CAR T Cells and T-Cell Therapies for Cancer
2024 Standout
T-cell-engaging bispecific antibodies in cancer
2023 Standout
5 intermediate papers

Works of Shaji Kumar being referenced

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma
2022
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
2020 Standout
and 11 more

Author Peers

Author Last Decade Papers Cites
Shaji Kumar 22717 22231 13685 1.0k 33.9k
Philippe Moreau 18794 17218 13840 989 31.1k
Philip R. Greipp 17668 17196 10694 323 27.8k
Martha Q. Lacy 15411 16326 9217 549 24.7k
S. Vincent Rajkumar 37605 32817 20954 885 52.1k
Bart Barlogie 30064 24023 18006 696 41.6k
Angela Dispenzieri 24765 30738 15184 961 46.2k
Rafaël Fonseca 17129 15877 9728 438 25.1k
Morie A. Gertz 20063 29428 13328 930 42.6k
Paul G. Richardson 31679 33345 22126 1.1k 50.7k
Nikhil C. Munshi 21055 24747 16361 790 39.2k

All Works

Loading papers...

Rankless by CCL
2026